VSH Q1 Earnings Call: Guidance Rises on AI and Industrial Demand, Tariff Impacts Limited
Is now the time to buy VSH? Find out in our full research report (it's free).
Revenue: $715.2 million vs analyst estimates of $719.2 million (4.2% year-on-year decline, 0.6% miss)
Adjusted EPS: -$0.03 vs analyst estimates of -$0.02 (in line)
Revenue Guidance for Q2 CY2025 is $760 million at the midpoint, roughly in line with what analysts were expecting
Operating Margin: 0.1%, down from 5.7% in the same quarter last year
Inventory Days Outstanding: 112, up from 110 in the previous quarter
Market Capitalization: $2.16 billion
Vishay Intertechnology's first quarter was characterized by steady demand in key end markets and ongoing inventory normalization. CEO Joel Smejkal explained that while automotive revenues softened due to new OEM contract pricing and holiday-related factors in Asia, industrial demand rebounded in Europe and smart grid infrastructure projects drove new orders. The company also noted a sequential improvement in point-of-sale activity at distributors and a positive book-to-bill ratio, which Smejkal attributed to expanded SKU offerings and improved supply chain positioning. Management acknowledged that average selling prices declined due to annual negotiations, but maintained that broad-based demand signals are stabilizing.
Looking ahead, Vishay Intertechnology's management expects second quarter growth to be driven by ongoing momentum in AI server and smart grid infrastructure markets, alongside incremental gains in distributor and industrial channels. Smejkal highlighted, 'We see the demand for Vishay products more in line with end market consumption than at any time in the past two years of inventory digestion.' CFO Dave McConnell detailed that tariff-related revenue will be offset by minimal gross margin impact due to established pass-through processes. The company remains focused on capacity expansion, particularly in high-growth areas like silicon carbide and automotive-grade products, while remaining attentive to evolving geopolitical and supply chain dynamics.
Management cited improved order intake in industrial, smart grid, and AI segments, while addressing the ongoing impacts of tariffs and pricing negotiations.
Industrial and Smart Grid Momentum: Vishay saw stronger industrial demand, especially in Europe, with new wins in smart grid projects and the company's first U.S. high-voltage DC power transmission program. These long-term infrastructure projects are expected to provide stable demand regardless of short-term economic fluctuations.
AI Segment Growth: Shipments for AI server and power management components more than doubled from the previous quarter, with design activity expanding to edge servers, optical modules, and graphics cards. Management stressed that relationships with contract manufacturers in Asia are helping Vishay gain share in this fast-evolving segment.
Automotive and Aerospace Trends: Automotive revenues declined due to lower pricing in new OEM contracts and the Chinese New Year holiday, yet underlying electronic content growth in hybrid and EV platforms remains a tailwind. Aerospace and defense orders softened sequentially as distributors managed inventory, but design activity continues in next-generation military and satellite systems.
Tariff Impact Limited: New tariffs primarily affected a small portion of sales, with less than 4% of consolidated sales exposed to China-origin products sold into the U.S. The company's global manufacturing footprint allows flexible sourcing, and tariff surcharges are being passed through to customers with minimal impact on gross profit.
Distribution Channel Strategy: Vishay continued to add SKUs for distribution partners, supporting improved point-of-sale growth and inventory reductions in Europe and the Americas. The company is leveraging its expanded catalog to re-engage inactive customers and position itself for future share gains.
Vishay's outlook is anchored in expected demand from AI, industrial infrastructure, and ongoing capacity expansion, but tempered by tariff pass-throughs and cost pressures.
AI and Infrastructure Demand: The company anticipates continued strength in AI server components and smart grid infrastructure projects, which management believes will support sequential revenue growth and improved backlog visibility into the second half of the year.
Capacity Expansion Initiatives: Vishay is increasing investment in capacity, especially for silicon carbide products and automotive-grade components, aiming to support customer growth and win new design slots. The Newport facility and other global sites are expected to ramp utilization, though management cautions that gross margin neutrality at Newport is not expected until the first half of next year.
Tariffs and Cost Management: Despite higher tariffs on China-origin passives and semiconductors, management expects limited direct impact due to flexible sourcing and established pass-through mechanisms. However, input cost inflation and annual OEM pricing resets remain margin headwinds, with some cost reductions only partially realized in the near term.
In upcoming quarters, the StockStory team will be watching (1) the ramp-up and utilization progress at Vishay's Newport facility and its impact on margins, (2) sustained order visibility in AI and smart grid segments, and (3) the effectiveness of ongoing SKU expansion and distribution engagement. Additionally, we will track how the company manages input cost pressures and tariff-related sourcing, as well as progress on silicon carbide product launches.
Vishay Intertechnology currently trades at a forward EV-to-EBITDA ratio of 7.7×. Should you double down or take your chips? The answer lies in our full research report (it's free).
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Merging deep tech and biomedical science expertise, ChronicleBio aims to accelerate breakthroughs for millions living with complex chronic conditions
New venture harnesses multi-omic data and AI to develop the largest platform on complex chronic illnesses to drive breakthroughs in POTS, ME/CFS, Long COVID, and other neuroimmune disorders SAN FRANCISCO, Aug. 5, 2025 /PRNewswire/ -- ChronicleBio, a techbio startup focused on radically accelerating insights on neuroimmune disorders, officially launched Tuesday with a bold mission: to build the world's richest, AI-ready data platform for historically overlooked conditions like POTS, ME/CFS, Long COVID, and other complex chronic conditions. ChronicleBio is uniquely led by a founding team that unites elite tech, healthcare, and life sciences: Fidji Simo (Co-founder), current CEO of Instacart and the incoming CEO of OpenAI's applications division, brings deep expertise in consumer-scale technology, product innovation, and health systems transformation. Rohit Gupta (Co-founder & CEO), a biobanking and precision medicine leader who previously oversaw centers at Stanford and UCSF, is the leading scientific and strategic force behind ChronicleBio. Rishi Reddy (Co-founder & Executive Chairman), of Tarsadia Investments, brings an entrepreneurial and venture-backed perspective and a track record in health and life sciences investing. Together, they are tackling a critical gap in biomedical research. ChronicleBio is creating a scalable, ethically driven data ecosystem, integrating clinical, molecular, biospecimen, and patient-reported insights to drive biomarker discovery, patient stratification, and precision therapeutic development. "Entire communities of patients have been ignored for too long, not because their conditions aren't debilitating and prevalent, but because the systems weren't built to understand them," said Fidji Simo, co-founder of ChronicleBio. "ChronicleBio is developing a future where patients can enlist in research, and where the data we collect from them goes directly towards better diagnostics and therapeutics. By building these critical missing datasets and leveraging the massive advances in AI, we aim to accelerate the path to cures." These complex chronic conditions impact nearly 300 million people worldwide, but remain woefully understudied, leaving patients hopeless and without meaningful treatments. It's a disease space desperate for data, and ChronicleBio is offering the scalable solutions to provide it. "Neuroimmune disorders remain some of the most poorly understood in medicine and not for lack of interest, but because the underlying data simply doesn't exist at the scale or structure required for serious breakthroughs," said Rohit Gupta, co-founder and CEO of ChronicleBio. "We're empowering patients and clinicians to get involved in this effort to grow our research-grade biobank and AI-ready data platform so we can close that gap and provide the tools to finally interrogate these diseases with scientific rigor and precision, bringing an end to complex chronic conditions." ChronicleBio partners directly with patients, clinics, and research collaborators to generate longitudinal, multi-modal datasets, including genomics, immune profiling, and real-world outcomes designed for exploration and clinical trial readiness. Its platform is already being used in multiple high-integrity clinics in the U.S. and India, as well as through research collaborations with thousands of patients contributing data and biosamples. "We're creating an ecosystem with global reach, designed not just to generate data, but to fundamentally shift how we discover, develop, and deliver treatments at scale. The opportunity for impact—scientifically, medically, and societally—is enormous," said Rishi Reddy, co-founder and Executive Chairman of ChronicleBio. "We're building the foundational infrastructure for a massive medical need that has been hiding in plain sight." ChronicleBio's founding vision isn't just ambitious. It's personal. Both Simo and Reddy have been diagnosed with at least one of the very conditions the company is focused on researching. Gupta's family also suffers from neuroimmune disorders. The group's world-class expertise is outshined only by its heartfelt determination to rewrite the scientific narrative for the millions of patients overlooked by traditional research and transform lived experience into actionable discovery. ChronicleBio's approach includes: A global biobank platform collecting and connecting data on neuroimmune illnesses A proprietary, AI-ready data engine designed to integrate multi-omic, clinical, and real-world evidence Strategic partnerships with clinics, research consortia, and biotech sponsors looking to unlock hard-to-crack therapeutic areas A decentralized clinical trial network accelerating drug development through real-world access to patients and clinicians For more information, visit or follow ChronicleBio on LinkedIn, X, Instagram, and Facebook. Media Contact:media@ View original content to download multimedia: SOURCE ChronicleBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Shopify Q2 Preview: Tariff Noise and GMV Leverage in Focus
Shopify (NASDAQ:SHOP) reports second-quarter 2025 earnings before the open on August 6. Analysts forecast EPS of $0.29 on approximately $2.54 billion in revenue, about 25% YoY growth. Shares are up roughly 92% over the past 12 months and 9% below its 52-week high hit in February 2025. Investor focus remains on GMV, monetization, and merchant exposure to trade friction. Last quarter, total GMV grew 23% to $75 billion. Analysts will look for continued momentum in platform sales, take?rate stability, and revenue per merchant, particularly within Merchant Solutions, where margins are more exposed to cross-border trade costs. Tariffs have become a merchant-level risk. Shopify executives highlighted at Q1 earnings that just 1% of GMV originates from Chinese imports, but cross-border commerce contributed 15% of total GMV. The elimination of the U.S. de minimis exemption for China means merchants now face duties on low-value imports. Shopify has responded with AI-powered tariff guidance tools and expanded duties?collection functionality at checkout to help merchants mitigate cost exposure and friction. AI and international merchant expansion also matter. Shopify continues to roll out AI tools to drive merchant efficiency and boost international cross-border sales. Investors will assess whether Q2 commentary confirms traction in these segments, especially Europe, Managed Markets, and new logistics partnerships, all critical to sustaining profitability as trade friction rises. At a valuation pricing in robust growth, Shopify needs Q2 commentary that reaffirms GMV momentum, merchant loyalty, and the value of its trade?navigation toolkit. Any sign of softening volume or take?rate pressure could signal vulnerability. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Rising Tariffs Undercut Caterpillar's Q2 Performance Even As Order Backlog Swells By $2.5 Billion
Caterpillar Inc. (NYSE:) reported second-quarter 2025 revenue of $16.569 billion, down 1 percent from $16.689 billion a year earlier, beating the analyst consensus of $16.17 billion. The adjusted earnings per share of $4.72 missed the $4.90 estimate. GAAP earnings per share were $4.62, compared with $5.48 in the prior-year period. GAAP operating profit was $2.860 billion, representing a 17.3% margin, a decrease of $622 million, or 18% YoY, compared with $3.482 billion. This was primarily due to unfavorable manufacturing costs, which the company repeatedly said "largely reflected the impact of higher tariffs.". Adjusted operating profit was $2.916 billion, with a 17.6% margin, down from 22.4% a year operating cash flow was $3.1 billion for the quarter. Machinery, Energy & Transportation (ME&T) free cash flow was $1.5 billion. The company ended the quarter with $5.4 billion in enterprise cash. During the period, Caterpillar repurchased $800 million of common stock and paid $700 million in dividends. Construction Industries posted sales of $6.190 billion, down 7% from $6.683 billion a year ago. Segment profit declined 29% to $1.244 billion, and the segment margin fell to 20.1% from 26.1%. Management attributed the margin pressure to unfavorable price realization and "unfavorable manufacturing costs largely reflected the impact of higher tariffs." Resource Industries reported sales of $3.087 billion, a 4% decrease year-over-year. Segment profit fell 25% to $537 million. The company again cited "unfavorable manufacturing costs largely reflected the impact of higher tariffs" as a key driver of the profit decline. View more earnings on CAT Energy & Transportation generated $7.836 billion in sales, up 7% from $7.337 billion in the prior-year quarter. Segment profit rose 4% to $1.585 billion, though the margin declined slightly to 20.2%. Higher manufacturing costs due to tariffs contributed to the margin compression. Financial Products revenue rose 4% to $1.042 billion. Segment profit increased 9% to $248 million, driven by higher average earning assets and gains on equity securities, partially offset by increased provision for credit losses. Geographically, North America sales declined about 2 percent to approximately $8.9 billion, while Latin America revenue fell 4 percent. In contrast, EAME (Europe, Africa, Middle East) posted a 6 percent increase in regional sales, and Asia Pacific posted flat or unchanged revenue versus the prior-year quarter. Caterpillar said the order backlog increased by approximately $2.5 billion during the quarter across all primary segments. Outlook The company expects Q3 2025 incremental tariff costs to range between $400 million and $500 million. For the full year, it estimates net incremental tariff costs of $1.3 billion to $1.5 billion. Caterpillar anticipates full-year sales to be slightly higher than 2024 and expects ME&T free cash flow to be around the middle of its $5 billion to $10 billion targeted range. It reaffirmed that full-year adjusted operating profit margin is expected to be in the top half of the targeted range, excluding tariffs, and in the bottom half, including tariffs. In the conference call, the company stated, "Including the net impact from incremental tariffs, we expect third quarter enterprise adjusted operating profit margin to be lower versus the prior year." Price Action: At the last check on Tuesday, CAT shares were trading higher by 0.21% at $434.63. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? CATERPILLAR (CAT): Free Stock Analysis Report This article Rising Tariffs Undercut Caterpillar's Q2 Performance Even As Order Backlog Swells By $2.5 Billion originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data